Winter soil CO_2 efflux in two contrasting forest ecosystems on the eastern Tibetan Plateau, China

Significant CO2 fluxes from snow-covered soils occur in cold biomes. However, little is known about winter soil respiration on the eastern Tibetan Plateau of China. We therefore measured winter soil CO2 fluxes and estimated annual soil respiration in two contrasting coniferous forest ecosystems （a Picea asperata plantation and a natural forest）. Mean winter soil CO2 effluxes were 1.08 μmol m-2 s-1 in the plantation and 1.16 μmol m-2 s-1 in the natural forest. These values are higher than most reported winter soil CO2 efflux values for temperate or boreal forest ecosystems. Winter soil respiration rates were similar for our two forest ecosystems but mean soil CO2 efflux over the growing sea- son was higher in the natural forest than in the plantation. The estimated winter and annual soil effluxes for the natural forest were 176.3 and 1070.3 g m-2, respectively, based on the relationship between soil respiration and soil temperature, which were 17.2 and 9.7 % greater than their counterparts in the plantation. The contributions of winter soil respiration toannual soil efflux were 15.4 % tor the plantation and 16.5R for the natural forest and were statistically similar. Our results indicate that winter soil CO2 efflux from frozen soils in the alpine coniferous forest ecosystems of the eastern Tibetan Plateau was considerable and was an important component of annual soil respiration. Moreover, reforesta- tion （natural coniferous forests were deforested and refor- ested with P. asperata plantation） may reduce soil respiration by reducing soil carbon substrate availability and input.

病例对照Meta分析显示男性乳腺癌与女性乳腺癌预后相同(英文)

Objective: Male breast cancer (MBC) is a rare disease, and studies to compare the prognosis between the MBC and female breast cancer (FBC) available now were case-control studies and population-based studies, however, with controversial outcomes. To further investigate whether sex affects the prognosis of breast cancer, we performed a meta-analysis based on all the peered papers. Methods: The PubMed database was screened. Subsequently, the hazard ratios (HRs) for overall survival (OS) and disease special survival (DSS), were pooled using the Review Manager 5.0 package. Results: This study comprised of 254 MBC and 733 FBC patients enrolled in six case-control studies. There was no statistically significant heterogeneity among the trials for either outcome variable. The pooled HR showed that there was no significant difference in 5-year or 10-year DSS (HR: 1.25, 95% CI: 0.76-2.08; HR: 1.04, 95% CI: 0.68-1.59) and 5-year or 10-year OS (HR: 0.76, 95% CI: 0.51-1.14; HR: 0.74, 95% CI: 0.54-1.02) between MBCs and FBCs. Conclusion: MBC and FBC with similar prognosis are found in this meta-analysis based on only case-control studies which matched main potential prognostic factors such as age, clinical stage, and time at diagnosis.

单药健择治疗老年非小细胞肺癌荟萃分析(英文)

Objective:Gemcitabine,used as single agent for elderly patients with non-small cell lung cancer (NSCLC),was demonstrated effective in this population based on phase II studies.The aim of this study was to summarize all those phase II studies with the hope to get a comprehensive understanding of gemcitabine efficacy.Methods:The PubMed database was used to search all the papers on NSCLC associated with gemcitabine used as single agent in the first line setting till to March 31st,2010.And the medians and their 95% CI of overall response rate (ORR),disease control rate (DCR),progression free survival (PFS),and overall survival (OS) were calculated.Results:1.There were 7 papers including 410 patients with performance status (PS) ≤ 2 and advanced stage collected.2.The dose-intensities of gemcitabine were 843.75 mg/m 2 /week-1125 mg/m 2 /week in the 4-week schedule,and 666.7 mg/m 2 /week in the 3-week schedule.3.The median age was 73.8 (95% CI was 72.44,75.16) years old;36.1% (95% CI:31.4%,40.7%) of patients with stage IIIB and 60.5% (95% CI:55.8%,65.2%) of patients with stage IV;35.9% (95% CI:31.2%,40.5%) patients were adenocarcinomas and 43.7% (95% CI:38.9%,48.5%) patients were squamous cell carcinomas (SCCs).4.The ORR,DCR,PFS/TTP,and OS were 22.3% (95% CI:18.2%,26.5%),58.4% (95% CI:53.5%,63.4%),3.6 (95% CI:2.9,5.15) months and 6.68 (95% CI:5.4,8.11) months,respectively.Conclusion:Gemcitabine as single agent applied in this special population was effective and can be well tolerated under different doses and usage.

中国男性乳腺癌患者临床特征:公开发表文章的总结(英文)

Objective:The extremely low incidence of male breast cancer (MBC) leads to lack of prospective randomized phase III studies worldwide. Especially in China,all studies on Chinese patients with MBC were based on small sample size and single institute experience. The aim of this study was to provide overall view of characteristics of Chinese patients with MBC by means of summarizing all related papers published in Chinese journals. Methods: An online search was made in CBM,VIP,CNKI,and CBA databases to find all published articles of interest on Chinese patients with MBC. And eight subjects including the proportion of MBC in all breast cancer,age,tumor location,clinical stages,pathological subtypes,treatment modalities,ER/PR expression,and 5-year survival rate were selected to calculate the proportion and their 95% interval confidence. Results: There were 122 papers with 2584 patients enrolled. The basic features of Chinese patients with MBC included:(1) MBC only with a proportion of 1.06% of all the breast cancer; (2) The mean age at diagnosis was 57.6 years old; (3) Tumor mainly located in the areolar region (74.83%) with obvious nipple and/or skin involvement; (4) Nearly 62.62% patients were in early stage before accepting treatment; (5) Infiltrating ductal carcinoma accounted for 79.05% of all pathological subtypes; (6) ER/PR expression rate was 65.86%; (7) Radical resection was up to 86.06% in all surgical modalities; (8) The 5-year survival rate was 57.33%. Conclusion: The results showed in this study were an overall view of Chinese patients with MBC whose characteristics were similar to that reported in the West. Though this study provided a little bit stronger confidence than a single study collected in this paper,studies with more powerful evidence are urgently demanding in China.

贝伐珠单抗珠联合紫杉类方案治疗中国转移性乳腺癌患者疗效及其相关问题(英文)

Objective: Bevacizumab has been challenging in the treatment of metastatic breast cancer. To investigate its efficacy, optimal partner to combine with and maintenance therapy, we performed a retrospective study based on Chinese patients with metastatic breast cancer (MBC). Methods: Patients with MBC treated with bevacizumab-contained regimens at the Sun Yat-sen University Cancer Center from 2006 to 2010 were recruited to the study. The primary endpoints were overall survival (OS), time to progression (TTP), objective response rate (ORR), and disease control rate (DCR). These endpoints were analyzed using the Kaplan-Meier and Chi-squared tests, respectively. Results: (1) A total of 229 cycles of bevacizumab with a median cycle of 7 (1-34) were administered among 25 patients. (2) In the whole group, ORR and DCR were 60% (15/25) and 76% (19/25), respectively. The mTTP was 5 months (1-21), mOS from diagnosis was 48 months (13-172), mOS from bevacizumab administration was 24 months (1-45). (3) Both ORR (73.7% vs. 16.7%, P = 0.023) and DCR (94.7% vs. 33.3%, P = 0.005) were significant higher once patients treated with the combination of taxanes-based regimen and bevacizamab when compared with the combination with non-taxanes-based regimens. (4) In the taxanes-based group, no matter bevacizumab used in first line or non-first line, the differences of ORR (P = 0.637) and DCR (P = 0.316) were insignificant. However, the maintenance therapy with bevacizumab will bring more longer TTP (P < 0.001) than those without maintenance therapy. Conclusion: Taxanes-based regimens were the optimal candidate to combine with bevacizumab regardless the timing in palliative setting, however, the maintenance therapy with bevacizumab should be considered once indicated.

Bevacizumab在中国癌症患者中使用的安全性和有效性的荟萃分析(英文)

Objective: The aim of this study was to investigate the efficacy and safety profiles of bevacizumab, the commonly used monoclonal antibody and its safety profiles were challenging, based on Chinese cancer patients. Methods: All the papers studied on Chinese cancer patients treated by bevacizumab were found in both databases of Chinese journal database for fulltext and PubMed were collected. The commonly used efficacy index such as disease control rate (CR + PR + SD) and response rate (CR + PR) were analyzed, and the bevacizumab related side effects were analyzed too. Results: (1) There were ten original papers contained total 199 patients who were the candidates to analyze the safety profiles, and 115 patients with colorectal cancer in five papers who were candidates to analyze the efficacy. (2) Nine in ten papers set the dose of bevacizumab in 2.5 mg/kg/week - 5 mg/kg/week, and the biweekly was the standard chemotherapy interval. (3) The disease control rate and response rate in Chinese colorectal cancer patients were 85% (95% CI: 79%-92%) and 61% (95% CI: 52%-70%), respectively. (4) The side effects related to bevacizumab were rare and most of them were grades 1-2, and only one case with grade 4 bleeding was recorded and only two cases with discontinuation of bevacizumab since hemoplysis. Also, the grades 3-4 side effects related cytotoxic agents were not common. Conclusion: This study summarized the data of Chinese cancer patients treated by bevacizumab-contained regimens, and it showed that the monoclonal antibody was effective and safe for Chinese patients as the West patients.

Non-platinum doublets versus single agents in non-small cell lung cancer （NSCLC） patients with elderly age and/or poor performance status： a meta-analysis

学习的目的是在以前未经治疗的先进非小的房间肺癌症(NSCLC ) 把非铂马甲(马甲组) 的功效和毒性与一个非铂单身者代理人(单个代理人的组) 作比较的目的有老年龄或差的表演地位(PS ) 的病人。PubMed 数据库被屏蔽的方法。随后，为全面幸存( OS )的危险比率( HR )和没有前进的幸存( PFS )，为全面反应的相对风险( RR )评价( ORR )并且一个年幸存，并且为毒性的不同类型的机会比率( ORs )用评论经理 5.0 包裹被分享。这研究 1427 个病人包括了的结果在四注册了使随机化的控制试用。分享的 HR 证明马甲组能增加 ORR (P = 0.002 ) 没有异质(P = 0.64 ) ，并且可能改进 OS (P = 0.01 / P = 0.06 ) 与异质(P < 0.001 ) 。在 PFS 没有重要差别(P = 0.16 ) 并且一个年幸存(P = 0.25 ) 在二个治疗组之间。马甲组比单个代理人的组导致了更多的等级 3/4 嗜中性白血球减少症和 thrombocytopenia (P = 0.02 并且 P = 0.000，分别地) 。等级 3/4 贫血症的发生，呕吐，在二个治疗组之间的 mucositis，便秘，腹泻， neurotoxicity，过敏症，和疲劳是不足道的。结论除了嗜中性白血球减少症和 thrombocytopenia，非铂马甲能增加 ORR，和力量没有更多的副作用的增加，与老年龄或差的 PS 为 NSCLC 病人改进 OS；然而，马甲显示出嗜中性白血球减少症和 thrombocytopenia 的增加的率。马甲的增加不能改进 PFS 和一个年幸存。

Cetuximab联合化疗二线治疗6例非小细胞肺癌的近期疗效分析(英文)

Objective:Cetuximab combined with chemotherapy has been used to treat non-small cell lung cancer (NSCLC) in recent years, most of them were first line setting.This study was to summarize our experiences in treating NSCLC patients with cetuximab in the non-first line setting.Methods:From October 1st 2006 to December 31st 2009, six NSCLC patients were treated with cetuximab combined standard chemotherapy as non-first line setting in Sun Yat-sen University Cancer Center, China.The short-term efficacies and safeties were analyzed.Results:1.A total of 18 cycles of cetuximab treatment, with a median of two cycles in the whole group.2.There were 6 patients treated as non-first line setting, overall response rate (ORR) was 33.3% (2/6), disease control rate (DCR) was 33.3% (2/6), median time to progression (TTP) was 3.5 (3-4) months, and median OS was 18 (4-28) months.3.There were 50% (3/6) patients occurred acne-like rash within three weeks, their ORR was 66.7% (2/3), and DCR was 66.7% (2/3), however, both of ORR and DCR in patients who didn't occurred acne-like rash were 0% (0/3), the differences of ORR, DCR between two groups were in significant different (P=0.143).4.There was no treatment-associated death and no cetuximab-associated discontinuation.The incidence of acne-like rash was 50% occurred within three weeks, there were two patients suffered side effects associated with chemotherapy.Conclusion:The data of cetuximab application in non-first line setting for patients with NSCLC were rare, and the addition of cetuximab in those population was safe.

含Cetuximab方案治疗非肠癌消化道肿瘤近期疗效——单中心16例经验总结(英文)

Objective: Cetuximab is an effective medicine for colorectal cancer bearing wild type Kras. However, few studies of cetuximab on patients with noncolorectal gastrointestinal cancer were available now. The aim of this study was to summarize the efficacy and safety profiles base-on the experiences of 16 patients with noncolorectal gastrointestinal cancer accepted cetuximab-contained regimens treatment. Methods: The clinical data of all patients with noncolorectal gastrointestinal cancer treated by cetuximab combined with chemotherapy and/or radiotherapy from October 1st 2006 to Jun 30th 2009 in Sun Yat-sen University Cancer Center were collected. Results: (1) A total of 16 patients enrolled, including gastric cancer, esophageal carcinoma, pancreatic cancer and cholangiocarcinoma (8, 6, 1 and 1, respectively). The cetuximab was adminis- tered 92 cycles totally with median cycle of 4. (2) PR, SD and PD obtained in 4, 3 and 2 patients respectively in cetuximab + chemotherapy group. The disease control rate, median TTP and median OS were 77.8% (7/9), 3.5 months and 3.5 months, respectively. (3) Both of patients in cetuximab + radiotherapy group achieved PR with median TTP of 4 months and 7 months, with median OS of 14 and 28 months, respectively. (4) In evaluable patients, 3 PR obtained in first-line setting, 1 PD and 1 SD achieved in second-line setting, 2 SD and 1 PD appeared in third-line and more than third-line setting. (5) The commonly side effect was neutropenia, however, rash and hypomagnesemia were the common side effects related to cetuximab. Conclusion: Cetuximab-contained regimens show a promising disease control rate, especially in first-line setting, in patients with noncolorectal gastrointestinal cancer, and the side effects both related to cytotoxic agents and related to cetuximab itself is tolerable and manageable. Of course, more phase Ⅲ clinical trails are needed urgently.

西妥昔单抗联合化疗一线治疗非小细胞肺癌疗效:基于公开发表文章的总结(英文)

Objective:The combination of cetuximab with standard chemotherapy was not widely studied though it was recommended by NCCN 2009 to apply in non-small cell lung cancer(NSCLC) first-line setting.The aim of this study was to summary the efficacy and safety profiles of all the NSCLC patients available in openly published papers treated with above mentioned regimens.Methods:The PubMed database was used to search all the papers on NSCLC associated with cetuximab treatment, and only the clinical trails applied cetuximab combined with doublets cytotoxic chemotherapy in first-line setting till to 30 November 2009 were collected.And the medians and their 95% CI of objective response rate(ORR), progression free survival(PFS), overall survival(OS), and the common adverse events were calculated.Results:(1) Eight papers including 1032 patients were collected, and all cases were at advanced stage.(2) The ratio of male and female patients was 1.6, 50.1% patients were adenocarcinoma and 28.2% patients were squamous cell carcinoma(SCC), 90.0% patients were PS = 0-1, and 78.2% patients were white ethnic.(3) The disease control rate(DCR), ORR, PFS, and OS were 65.2%(95% CI:60.7%-69.7%), 33.2%(95% CI:30.3%-36.1%), 5.0 months(95% CI:4.7-5.3) and 10.9 months(95% CI:9.6-12.2), respectively.Conclusion:This is the first study to summarize the efficacy and safety profiles of cetuximab combined with chemotherapy in NSCLC first-line setting based on all available patients.The addition of cetuximab caused promising prognosis and acceptable side effects excepting higher incidence of neutropenia, and febrile neutropenia.

Characterization and quantification of two acylated flavonol glycosides from Camellia sinensis and their antibacterial effect on oral pathogens

Acylated flavonol glycosides(AFGs)are a new group of flavonoids with multiple pharmacological functions.In the present work,two AFGs were isolated with a combined chromatography technology from Camellia sinensis and identified as quercetin tetraglycosides with one p-coumaryl moiety(F1)and kaempferol tetraglycosides with one p-coumaryl moiety(F2)by ultra-performance liquid chromatography tandem mass spectrometry(UPLC-MS/MS)and nuclear magnetic resonance(NMR).F1 and F2 with high purity and quantity can be obtained through relatively simple steps,which is of great significance in industrial production and application.The quantification of two AFGs in different tea cultivars and different season samples was conducted using the high-performance liquid chromatography(HPLC)method.Among fifty tested tea cultivars,the contents of F1 and F2 were extremely high in'Zhenghe Dabaicha'and'Wannong 95',but these were undetectable in some tea cultivars.Relatively high contents of AFGs were found in autumn harvested tea samples which might be related to sunlight irradiation.Further in vitro experiments showed that F1 and F2 monomers were effective on inhibiting growth and biofilm development of Porphyromonas gingivalis and Fusobacterium nucleatum.This antibacterial activity was proven to involve the chelation of iron.These results provide useful information on AFGsrich tea resources and new insights of AFGs into effective agents against oral diseases.

High-entropy(La_(0.2)Nd_(0.2)Sm_(0.2)Gd_(0.2)Yb_(0.2))_(2)(Zr_(0.75)Ce_(0.25))_(2)O_(7)thermal barrier coating material with significantly enhanced fracture toughness

Poor fracture toughness leads to premature failure of La_(2)(Zr_(0.75)Ce_(0.25))_(2)O_(7)(LCZ)ther-mal barrier coatings in an elevated temperature service environment.A novel coating material,namely(La_(0.2)Nd_(0.2)Sm_(0.2)Gd_(0.2)Yb_(0.2))_(2)(Zr_(0.75)Ce_(0.25))_(2)O_(7)(LNSGY)based on the high-entropy con-cept,was successfully fabricated by solid-state sintering.The microstructure of LCZ and LNSGY was investigated by X-Ray Diffraction(XRD),Raman Spectrometer(RS),Transmission Electronic Microscopy(TEM)and Scanning Electron Microscopy(SEM).The fracture toughness of the LCZ and LNSGY ceramics was evaluated.The LNSGY has excellent high-temperature phase stability,and the grain size of LNSGY ceramic is smaller than that of LCZ ceramic at an elevated temper-ature due to the sluggish diffusion effect.Compared with LCZ(fracture toughness is(1.4±0.1)MPa·m^(1/2)),the fracture toughness of LNSGY is significantly enhanced(fracture toughness is(2.0±0.3)MPa·m^(1/2)).Therefore,the LNSGY can be a promising advanced thermal barrier coat-ing material in the future.

日本构建“民族文明秩序”的逻辑冲突与矛盾心态——以近代博览会上的阿伊努人种展示为例

近代世界博览会上的人种展示曾将社会达尔文主义作为理论依据,甄选、分类与展示被标签化为“野蛮”“原始”民族的身体与文化,以此将“文明”与白色人种的优越性挂钩。而明治维新后致力于“文明开化”的日本效尤西方这一“人类动物园”式的展示方法,通过在世界博览会上展示生理特征接近于白种人的北海道原住民阿伊努人,试图彰显作为黄种人的“和人”的优越性及其文明化的成果。随着这一意欲跻身“人种等级”顶端的展示方式受到西方的排斥,日本逐渐将阿伊努的展示舞台转向国内,并将其与当时的其他殖民地原住民并置,为日本在亚洲实施的“民族同化”政策正名。这种策略的转换凸显了近代日本企图构建一个“日本民族”作为东亚盟主、与白种人平等对话的话语体系,从而跃迁以欧美为中心的人种政治乃至文明秩序。

Digital quantum simulation of Floquet topological phases with a solid-state quantum simulator

Harnessing the dynamics of complex quantum systems is an area of much interest and a quantum simulator has emerged as a promising platform to probe exotic topological phases.Since the flexibility offered by various controllable quantum systems has helped gain insight into the quantum simulation of such complicated problems,an analog quantum simulator has recently shown its feasibility to tackle the problems of exploring topological phases.However,digital quantum simulation and the detection of topological phases still remain elusive.Here,we develop and experimentally realize the digital quantum simulation of topological phases with a solid-state quantum simulator at room temperature.Distinct from previous works dealing with static topological phases,the topological phases emulated here are Floquet topological phases.Furthermore,we also illustrate the procedure of digitally simulating a quantum quench and observing the nonequilibrium dynamics of Floquet topological phases.Using a quantum quench,the 0-andπ-energy topological invariants are unambiguously detected through measuring time-averaged spin polarizations.We believe our experiment opens up a new avenue to digitally simulate and detect Floquet topological phases with fast-developed programmable quantum simulators.

Pulse-width-induced polarization enhancement of optically pumped N-V electron spin in diamond

The nitrogen-vacancy(N-V)center in diamond is a widely used platform for quantum information processing and sensing.The electron-spin state of the N-V center could be initialized,read out optically,and manipulated by resonate microwave fields.In this work,we analyze the dependence of electron-spin initialization on widths of laser pulses.We build a numerical model to simulate this process and to verify the simulation results in experiments.Both simulations and experiments reveal that shorter laser pulses are helpful to the electron-spin polarization.We therefore propose to use extremely short laser pulses for electron-spin initialization.In this new scheme,the spin-state contrast could be improved about 10%in experiments by using laser pulses as short as 4 ns in width.Furthermore,we provide a mechanism to explain this effect,which is due to the occupation time in the meta-stable spin-singlet states of the N-V center.Our new scheme is applicable in a broad range of N-V-based applications in the future.